Patient-derived Organoids of Lung Cancer to Test Drug Response
Trial Parameters
Brief Summary
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Eligibility Criteria
Inclusion Criteria: * Histologically proven lung cancer * Age ≥ 18 * Written informed and signed consent * Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour Exclusion Criteria: * Less than 18 years of age * Not able to give informed consent (language, intellectual capacities, etc.) * Not accessible to biopsy and/or surgery sample * Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.